title: Acute dysphoric mania: treatment response to olanzapine versus placebo.
abstract: A substantial number of patients with mania have significant concomitant depressive features, and they may respond differently to mood stabilizers than patients with pure mania. This post-hoc analysis explored the response characteristics of olanzapine versus placebo in bipolar I manic patients with dysphoric and nondysphoric mania (differentiated by baseline Hamilton Depression Rating Scale [HAM-D] score of >20). Two similar, double-blind, randomized trials comparing olanzapine, 5-20 mg, to placebo were pooled for these analyses (N = 246). Mean changes in Young-Mania Rating Scale (Y-MRS) and HAM-D scores during 3 weeks of treatment were examined. Twenty-eight percent of patients had dysphoric mania (olanzapine, n = 33; placebo, n = 35). Among these patients, olanzapine-treated patients had greater improvement within 1 week than did placebo-treated patients on both mania ratings (Y-MRS: -9.7 vs. -3.0 points; = 0.011) and depressive symptom ratings (HAM-D: -9.9 vs. -5.4 points; = 0.025). Among those manic subjects without prominent depressive symptoms (olanzapine, n = 91; placebo, n = 87), mean Y-MRS improvement from baseline to endpoint with olanzapine (-11.5 points) versus placebo (-6.13 points) was comparable to the improvement seen with olanzapine versus placebo in the dysphoric mania subgroup ( = 0.476, test of interaction). In acutely ill manic patients with significant depressive symptoms, olanzapine demonstrated a broad spectrum of efficacy, effectively treating both manic and depressive symptoms. The magnitude of the antimanic response appears similar, regardless of baseline depressive features. Additional experience with putative mood stabilizers and atypical agents in mixed mania should include an exploration of their efficacy in treating both manic and depressive mood symptoms.
authors.affiliation: Lilly Research Laboratories, Indianapolis, Indiana 46285, USA. BAKER@Lilly.com
authors.forename: Robert W
authors.initials: RW
authors.lastname: Baker
authors.forename: Mauricio
authors.initials: M
authors.lastname: Tohen
authors.forename: Jan
authors.initials: J
authors.lastname: Fawcett
authors.forename: Richard C
authors.initials: RC
authors.lastname: Risser
authors.forename: Leslie M
authors.initials: LM
authors.lastname: Schuh
authors.forename: Eileen
authors.initials: E
authors.lastname: Brown
authors.forename: Virginia L
authors.initials: VL
authors.lastname: Stauffer
authors.forename: Lixin
authors.initials: L
authors.lastname: Shao
authors.forename: Gary D
authors.initials: GD
authors.lastname: Tollefson
mesh_terms: D000208:Acute Disease; D000339:Affect / Q000187:drug effects; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D001569:Benzodiazepines; D001714:Bipolar Disorder / Q000175:diagnosis / Q000188:drug therapy* / Q000523:psychology; D006801:Humans; D000077152:Olanzapine; D010890:Pirenzepine / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D011569:Psychiatric Status Rating Scales; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome
chemical_list: D014150:Antipsychotic Agents; D001569:Benzodiazepines; D010890:Pirenzepine; D000077152:Olanzapine